Skip to content
Review Open access

Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies

Oct 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 48 references
Medicine

TL;DR

Prospective studies should use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges, as well as define a practical framework for biomarker-guided immunotherapy.

Abstract

Osteosarcoma remains a therapeutically difficult malignancy, particularly after metastatic relapse, and immune checkpoint blockade or adoptive cell therapy has not reproduced the durable responses achieved in more immunogenic cancers. The central translational problem is not a complete absence of immune activity, but marked interpatient, intratumoral, and spatial heterogeneity in immune access, antigen presentation, myeloid suppression, stromal exclusion, and target-antigen expression. This Mini Review synthesizes recent single-cell and spatial profiling studies with tissue, circulating, and clinical biomarker evidence to define a practical framework for biomarker-guided immunotherapy. Osteosarcoma ecosystems can contain lymphoid-excluded, myeloid-dominant, angiogenic-hypoxic, checkpoint-rich, and antigen-high states that may coexist within the same patient. Consequently, programmed death-ligand 1 (PD-L1) alone is unlikely to function as a reliable treatment-selection marker. A composite assessment integrating human leukocyte antigen (HLA) class I and antigen-processing competence, CD8/regulatory T-cell topology, macrophage and myeloid-derived suppressor cell programs, vascular and extracellular-matrix barriers, and quantitative surface-antigen density is more biologically defensible. Dynamic measurements, including circulating tumor DNA, soluble B7-H3, exosomal immune signals, and serial imaging, may complement tissue profiling but remain investigational. Clinical experience with checkpoint inhibitors, antiangiogenic combinations, mifamurtide, HER2-directed approaches, and emerging B7-H3-, GD2-, ALPL-1-, CD166-, IL-11Ralpha-, and NKG2D-based cellular therapies underscores the need to match mechanism to phenotype. Prospective studies should therefore use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges.

Read PDF

Similar papers

Review Open access Nov 2026

Biomarkers for Cancer Immunotherapy: Advances, Challenges, and Clinical Applications

Cancer immunotherapy has revolutionized oncology by harnessing the immune system to recognize and eliminate malignant cells. Despite remarkable clinical successes, a substantial proportion of patients fail to respond or develop resistance, highlighting the urgent need for reliable biomarkers to guide patient selection,...

Adeel Ahmed, Faridul Haq · 0 citations
Review Open access Oct 2026

Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation

A precision-immunotherapy framework is proposed in which treatment selection and sequencing could be informed by evolving immune states, and this framework complements established treatment approaches and defines testable hypotheses for prospective clinical studies.

S. M. Nashir Udden, Monira Obaid, Laurentiu M. Pop et al. · 0 citations
Review Open access Oct 2026

Cell-based therapies for malignant glioma

Abstract Despite innovative progress, cellular therapies have not produced durable, population-level survival gains in glioblastoma. Across 3 major modalities, engineered effectors such as chimeric antigen receptor T cell (CAR-T) and natural killer (NK) cells, immune-education platforms such as dendritic and whole-cell...

Rachael Mooney, E. A. Abd El-Fattah, G. Ngai et al. · 0 citations
Review Nov 2026

Immunotherapy for gliomas: from checkpoint blockade to vaccines, cellular therapy, local immune engineering and combinations.

PURPOSE OF REVIEW Immunotherapy has transformed the treatment of many malignancies but has not yet produced comparable improvements in survival for patients with gliomas. This review examines the biological rationale for immunotherapy across molecularly defined gliomas, lessons from unsuccessful immune checkpoint inhib...

E. Owens, Maya S. Chandar, M. Khasraw · 0 citations
Review Open access Oct 2026

Prognostic scores and biomarkers in hematologic malignancies: current evidence and future perspectives

The advent of immunotherapy has profoundly transformed the therapeutic landscape of hematologic malignancies. A broad range of immune-based strategies, including immune checkpoint inhibitors and adoptive cell therapies based on both T cells and natural killer (NK) cells, have achieved unprecedented clinical outcomes in...

Eliot McDonald, E. Marcenaro, Philippe Robert et al. · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.